BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer
Phase IIa Study of the Efficacy of Single Agent BGJ398 (Infigratinib) in FGFR1-3 Translocated, Mutated, or Amplified Squamous Cell Carcinoma of the Head and Neck
Sponsor: Novartis
Terminated
Study stopped due to poor enrollment.
Other terminated trials from Novartis
A PHASE2 clinical study on FGFR Gene Amplification and FGFR1 Gene Amplification, this trial is terminated or withdrawn. The trial is conducted by Novartis and has accumulated 10 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE2
-
May 2019 — Jan 2021 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
▶ Show 5 earlier versions
-
Jul 2018 — May 2019 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jun 2018 — Jul 2018 [monthly]
Not Yet Recruiting PHASE2
-
May 2017 — Jun 2018 [monthly]
Not Yet Recruiting PHASE2
-
Feb 2017 — May 2017 [monthly]
Not Yet Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis
- University of Chicago
For direct contact, visit the study record on ClinicalTrials.gov .